Roche Aktie News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PA...

Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies.

Der Pharmakonzern Roche CH0012032048 wird mit seinem Parkinson-Kandidaten Prasinezumab eine zulassungsrelevante Phase-III-Studie starten.

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical tr...

Der schweizerische Pharmakonzern Roche CH0012032048 stellt die Verabreichung der Gentherapie Elevidys zur Behandlung von Duchenne-Muskeldystrophie (DMD) bei nicht-gehfähigen Patienten ein.

JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed a full transition from Siemens to Roche Diagnostics systems in under 6 months.

The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansion in emerging markets. This comprehensive report covers market segments, regional insights, and profiles of major players like Roche and Siemens. The global oncology diagnostics market is projecte...

The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric arc furnaces and hydrogen-based production, aiming to lower carbon emissions in steel manufacturing. Major investments and governmental support bolster this shift toward sustainability. Key regions ...